Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Emilio Iannitto¹, Simone Ferrero², Côme Bommier³, Daniela Drandi², Martina Ferrante², Krimo Bouabdallah⁴, Sylvain Carras⁵, Guido Gini⁶, Vincent Camus⁷, Salvatrice Mancuso⁸, Luigi Marcheselli⁹, Angela Ferrari¹⁰, Michele Merli¹¹, Benoit Tessoulin¹², Caterina Stelitano¹³, Kheira Beldjord¹⁴, Giovanni Roti¹⁵, Fabrice Jardin⁶, Barbara Castagnari¹⁶, Francesca Palombi¹⁷, Lucile Baseggio¹⁸, Alexandra Traverse-Glehen¹⁹, Claudio Tripodo²⁰, Anna Marina Liberati²¹, Margherita Parolini²², Sara Usai²³, Caterina Patti²⁴, Massimo Federico²⁵, Maurizio Musso²⁶, Marco Ladetto²⁷, Emanuele Zucca²⁸, Catherine Thieblemont³

Affiliations

¹ La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo, Italy; Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo. emilio.iannitto@gmail.com.
² Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino.
³ Universitè Paris Citè, Paris, France; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris.
⁴ CHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire, Pessac.
⁵ University Grenoble Alpes, Institute For Advanced Biosciences, INSERM U1209, CNRS UMR 5309, University Hospital, Molecular Biology and Hematology Departments, Grenoble.
⁶ Ematologia AOU delle Marche, Ancona.
⁷ Department of Hematology, Centre Henri Becquerel, Rouen.
⁸ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo.
⁹ Fondazione Italiana Linfomi ETS, Modena.
¹⁰ Azienda Unitá Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia.
¹¹ Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese.
¹² Nantes University Hospital and CRC2 NA, Nantes.
¹³ UO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria.
¹⁴ Universitè Paris Citè, Paris.
¹⁵ Dipartimento di Medicina e Chirurgia, Universitá di Parma, AOU di Parma, Parma.
¹⁶ Department of Hematology, Ravenna Hospital, Ravenna.
¹⁷ Hematology Unit, IRCCS Regina Elena National Cancer Institute, Roma.
¹⁸ Laboratoire d'Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon.
¹⁹ Service d'Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon.
²⁰ Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo.
²¹ Oncohematology Unit, University of Perugia, Azienda Ospedaliera S. Maria, Terni.
²² Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"- IRST, Meldola.
²³ Ospedale Oncologico A. Businco, Cagliari.
²⁴ U.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo.
²⁵ CHIMOMO Department, University of Modena and Reggio Emilia, Modena.
²⁶ La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo.
²⁷ University of Eastern Piedmont, Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria.
²⁸ IOSI, Oncology Institute of Southern Switzerland and IOR, Institute of Oncology Research IELSG International Extranodal Lymphoma Study, Bellinzona.

PMID: 40165734
PMCID: PMC11959258
DOI: 10.3324/haematol.2024.287031

Published Erratum

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Emilio Iannitto et al. Haematologica. 2025.

. 2025 Apr 1;110(4):1048-1049.

doi: 10.3324/haematol.2024.287031. Epub 2025 Apr 1.

Authors

Affiliations

¹ La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo, Italy; Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo. emilio.iannitto@gmail.com.
² Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino.
³ Universitè Paris Citè, Paris, France; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris.
⁴ CHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire, Pessac.
⁵ University Grenoble Alpes, Institute For Advanced Biosciences, INSERM U1209, CNRS UMR 5309, University Hospital, Molecular Biology and Hematology Departments, Grenoble.
⁶ Ematologia AOU delle Marche, Ancona.
⁷ Department of Hematology, Centre Henri Becquerel, Rouen.
⁸ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo.
⁹ Fondazione Italiana Linfomi ETS, Modena.
¹⁰ Azienda Unitá Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia.
¹¹ Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese.
¹² Nantes University Hospital and CRC2 NA, Nantes.
¹³ UO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria.
¹⁴ Universitè Paris Citè, Paris.
¹⁵ Dipartimento di Medicina e Chirurgia, Universitá di Parma, AOU di Parma, Parma.
¹⁶ Department of Hematology, Ravenna Hospital, Ravenna.
¹⁷ Hematology Unit, IRCCS Regina Elena National Cancer Institute, Roma.
¹⁸ Laboratoire d'Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon.
¹⁹ Service d'Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon.
²⁰ Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo.
²¹ Oncohematology Unit, University of Perugia, Azienda Ospedaliera S. Maria, Terni.
²² Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"- IRST, Meldola.
²³ Ospedale Oncologico A. Businco, Cagliari.
²⁴ U.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo.
²⁵ CHIMOMO Department, University of Modena and Reggio Emilia, Modena.
²⁶ La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo.
²⁷ University of Eastern Piedmont, Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria.
²⁸ IOSI, Oncology Institute of Southern Switzerland and IOR, Institute of Oncology Research IELSG International Extranodal Lymphoma Study, Bellinzona.

PMID: 40165734
PMCID: PMC11959258
DOI: 10.3324/haematol.2024.287031

No abstract available

PubMed Disclaimer

Erratum for

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Haematologica. 2024 Jul 1;109(7):2297-2302. doi: 10.3324/haematol.2023.284109. Haematologica. 2024. PMID: 38497158 Free PMC article. Clinical Trial. No abstract available.

References

1. Iannitto E, Ferrero S, Bommier C, et al. . Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Haematologica. 2024;109(7):2297-2302. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Pagepress Publications
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Affiliations

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Authors

Affiliations

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources